Monday, October 14, 2019
Home Partner Profiles Institute for Cardiogenetics: at the forefront of cardiovascular genomics research

Institute for Cardiogenetics: at the forefront of cardiovascular genomics research

Atherosclerosis and its most disabling sequelae, coronary artery disease (CAD) and myocardial infarction (MI), are leading causes of death in Europe. Until now, preventive and therapeutic interventions for these diseases aim at ameliorating the effects of established cardiovascular risk factors.

Key discoveries

More recently, results of genome-wide association (GWA) studies added to our understanding of etiological mechanisms leading to atherosclerosis. At present, over 150 CAD/MI risk loci have been identified, the majority through efforts led by members of the Institute for Cardiogenetics.

Some genes at these loci work through known risk factors such as lipids and, in fact, are already established or evolving treatment targets. However, this is not true for the majority of risk variants, which implies that key pathways leading to atherosclerosis are yet to be exploited for therapeutic intervention.

To achieve this goal, we integrate bioinformatical, epidemiological, clinical and experimental data and propose to elucidate the functional basis of already-known genetic loci, as well as identify novel pathways to further understand the pathomechanisms leading to these life-threatening diseases.

To accomplish this task, the Institute for Cardiogenetics hosts an interdisciplinary as well as international research team of 30 scientists, PhD and MD students and technicians.

Cardiovascular risk and research

We apply in silico (integrative genomics) as well as in vitro and in vivo methods (experimental genomics) to further unravel the genetics of cardiovascular diseases.

We are funded by national (BMBF, DFG) and international (EU, Fondation Leducq) agencies as well as local funding (University of Lübeck).

Importantly, we are part of the NCCR (partner site Hamburg, Kiel, Lübeck) within the DZHK e. V. (German Center for Cardiovascular Research) and the Excellence Cluster “Inflammation at Interfaces”.

The Institute for Cardiogenetics is engaged in large networks of national and international collaborations (like CARDIoGRAM, CARDIoGRAMplusC4D, and GIANT) and participates in data and sample exchange.

  • Monogenic and complex genetics;
  • Genome-wide association studies;
  • Phenome-wide association studies;
  • Next-generation sequencing;
  • Animal models to study cardiovascular gene function;
  • Systems-genetic approaches;
  • RNA-therapy approaches.
  • Genetics of monogenic and complex cardiovascular diseases, especially atherosclerosis and myocardial infarction;
  • Genome-wide association (GWA) and NGS studies in large cohorts and extended families;
  • Establishment of animal models (mice and zebrafish) to study atherosclerosis;
  • Understanding principle molecular mechanisms leading to disease;
  • Translation of genetic findings into new therapeutically and diagnostically products.

Profile in Health Europa Quarterly – Issue 5
Inside Front Cover in Health Europa Quarterly – Issue 6
Profile in Health Europa Quarterly – Issue 8
Profile in Health Europa Quarterly – Issue 9

Partner eBooks

Institute for Cardiogenetics – unravelling the genetics of cardiovascular disease

Cardiovascular disease (CVD) is a major global killer, but little is known about the exact causes. The Institute for Cardiogenetics aims to understand the...

Pin It on Pinterest